Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado reduced its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 6.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,948 shares of the biopharmaceutical company’s stock after selling 2,614 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Royalty Pharma were worth $1,080,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of RPRX. Versant Capital Management Inc increased its holdings in shares of Royalty Pharma by 5,215.0% during the 2nd quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,043 shares during the last quarter. Gladius Capital Management LP acquired a new stake in Royalty Pharma during the second quarter worth $32,000. Fidelis Capital Partners LLC acquired a new stake in Royalty Pharma during the first quarter worth $46,000. GAMMA Investing LLC raised its position in Royalty Pharma by 172.5% in the first quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 1,037 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Royalty Pharma by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,807 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 802 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $27.71 on Wednesday. Royalty Pharma plc has a fifty-two week low of $25.20 and a fifty-two week high of $31.66. The company has a 50 day moving average price of $28.02 and a 200 day moving average price of $27.96. The stock has a market capitalization of $16.55 billion, a P/E ratio of 20.68, a price-to-earnings-growth ratio of 4.17 and a beta of 0.46. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.95 by $0.01. The business had revenue of $537.00 million during the quarter, compared to the consensus estimate of $600.83 million. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. During the same quarter in the previous year, the firm posted $0.85 earnings per share. Equities research analysts predict that Royalty Pharma plc will post 4.04 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 13th. Shareholders of record on Friday, August 16th were issued a dividend of $0.21 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $0.84 annualized dividend and a yield of 3.03%. Royalty Pharma’s dividend payout ratio (DPR) is 62.69%.

Analyst Ratings Changes

Several brokerages recently issued reports on RPRX. UBS Group lowered shares of Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective on the stock. in a report on Monday, June 3rd. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. Morgan Stanley lifted their target price on shares of Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. Finally, The Goldman Sachs Group upped their price target on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.